-
1
-
-
84932633475
-
Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis
-
Molina E, Del Rincon I, Restrepo JF, et al. Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis. Arthritis Care Res 2015;67:940-6.
-
(2015)
Arthritis Care Res
, vol.67
, pp. 940-946
-
-
Molina, E.1
Del Rincon, I.2
Restrepo, J.F.3
-
2
-
-
0029869174
-
The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial
-
van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
-
(1996)
Ann Intern Med
, vol.124
, pp. 699-707
-
-
Van Der Heide, A.1
Jacobs, J.W.2
Bijlsma, J.W.3
-
3
-
-
0035886157
-
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies
-
Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
-
(2001)
Am J Med
, vol.111
, pp. 446-451
-
-
Lard, L.R.1
Visser, H.2
Speyer, I.3
-
4
-
-
84877634558
-
Very early rheumatoid arthritis as a predictor of remission: A multicentre real life prospective study
-
Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013;72:858-62.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 858-862
-
-
Gremese, E.1
Salaffi, F.2
Bosello, S.L.3
-
5
-
-
3242886819
-
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
-
Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
-
(2004)
Rheumatology
, vol.43
, pp. 906-914
-
-
Nell, V.P.1
Machold, K.P.2
Eberl, G.3
-
6
-
-
84860920048
-
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): Post hoc analyses from the COMET study
-
Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012;71:989-92.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 989-992
-
-
Emery, P.1
Kvien, T.K.2
Combe, B.3
-
7
-
-
84877602545
-
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
-
Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 844-850
-
-
Detert, J.1
Bastian, H.2
Listing, J.3
-
8
-
-
31044442965
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
-
Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 26-37
-
-
Breedveld, F.C.1
Weisman, M.H.2
Kavanaugh, A.F.3
-
9
-
-
85037610933
-
Effect of disease duration on clinical outcomes in moderate rheumatoid arthritis patients treated with etanercept plus methotrexate in the Preserve study
-
Smolen J, Collier D, Szumski A, et al. Effect of disease duration on clinical outcomes in moderate rheumatoid arthritis patients treated with etanercept plus methotrexate in the Preserve study. Arthritis Rheumatol 2014;66.
-
(2014)
Arthritis Rheumatol
, vol.66
-
-
Smolen, J.1
Collier, D.2
Szumski, A.3
-
10
-
-
2342658406
-
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial
-
Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 1400-1411
-
-
Keystone, E.C.1
Kavanaugh, A.F.2
Sharp, J.T.3
-
12
-
-
0034082253
-
Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
-
Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 22-29
-
-
Anderson, J.J.1
Wells, G.2
Verhoeven, A.C.3
-
13
-
-
85069006546
-
Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
-
Soriano ER, Dellepiane A, Salvatierra G, et al. Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. Future Sci OA 2018;4.
-
(2018)
Future Sci OA
, vol.4
-
-
Soriano, E.R.1
Dellepiane, A.2
Salvatierra, G.3
-
14
-
-
84929028357
-
FRI0160 efficacy of abatacept in RA patients with an inadequate response to anti-TNF therapy regardless of reason for failure, or type or number of prior anti-TNF therapy used
-
Schiff M, Zhou X, Kelly S, et al. FRI0160 efficacy of abatacept in RA patients with an inadequate response to anti-TNF therapy regardless of reason for failure, or type or number of prior anti-TNF therapy used. Ann Rheum Dis 2008;67(Suppl 2).
-
(2008)
Ann Rheum Dis
, vol.67
-
-
Schiff, M.1
Zhou, X.2
Kelly, S.3
-
15
-
-
0037231533
-
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
-
Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 35-45
-
-
Weinblatt, M.E.1
Keystone, E.C.2
Furst, D.E.3
-
16
-
-
31144454164
-
Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
-
Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 227-233
-
-
Aletaha, D.1
Ward, M.M.2
-
17
-
-
38749129727
-
Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: A pooled analysis of clinical trial results
-
Aletaha D, Strand V, Smolen JS, et al. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 238-243
-
-
Aletaha, D.1
Strand, V.2
Smolen, J.S.3
-
18
-
-
79958840089
-
Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry
-
Furst DE, Pangan AL, Harrold LR, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res 2011;63:856-64.
-
(2011)
Arthritis Care Res
, vol.63
, pp. 856-864
-
-
Furst, D.E.1
Pangan, A.L.2
Harrold, L.R.3
-
19
-
-
84896861959
-
The effect of socioeconomic class and immigrant status on disease activity in rheumatoid arthritis: Data from BARFOT, a multi-centre study of early RA
-
Andersson ML, Bergman S, Söderlin MK. The effect of socioeconomic class and immigrant status on disease activity in rheumatoid arthritis: data from BARFOT, a multi-centre study of early RA. Open Rheumatol J 2013;7:105-11.
-
(2013)
Open Rheumatol J
, vol.7
, pp. 105-111
-
-
Andersson, M.L.1
Bergman, S.2
Söderlin, M.K.3
-
20
-
-
84959552894
-
Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice
-
Narváez J, Magallares B, Díaz Torné C, et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 2016;45:386-90.
-
(2016)
Semin Arthritis Rheum
, vol.45
, pp. 386-390
-
-
Narváez, J.1
Magallares, B.2
Díaz Torné, C.3
-
21
-
-
84946606033
-
RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEG (PEGol) rheumatoid arthritis-treated patients from a Spanish multicenter national database
-
Torrente-Segarra V, Urruticoechea Arana A, Sánchez-Andrade Fernández A, et al. RENACER study: assessment of 12-month efficacy and safety of 168 certolizumab PEG (PEGol) rheumatoid arthritis-treated patients from a Spanish multicenter national database. Mod Rheumatol 2016;26:336-41.
-
(2016)
Mod Rheumatol
, vol.26
, pp. 336-341
-
-
Torrente-Segarra, V.1
Urruticoechea Arana, A.2
Sánchez-Andrade Fernández, A.3
-
22
-
-
84926434271
-
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts
-
van Nies JAB, Tsonaka R, Gaujoux-Viala C, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 2015;74:806-12.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 806-812
-
-
Van Nies, J.A.B.1
Tsonaka, R.2
Gaujoux-Viala, C.3
-
23
-
-
0037216311
-
Contribution of patient related differences to multidrug resistance in rheumatoid arthritis
-
Morgan C, Lunt M, Brightwell H, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 2003;62:15-19.
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 15-19
-
-
Morgan, C.1
Lunt, M.2
Brightwell, H.3
-
24
-
-
84871033136
-
Forget personalised medicine and focus on abating disease activity
-
Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013;72:3-6.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 3-6
-
-
Smolen, J.S.1
Aletaha, D.2
-
25
-
-
27744514865
-
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
-
Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 3381-3390
-
-
Goekoop-Ruiterman, Y.P.M.1
De Vries-Bouwstra, J.K.2
Allaart, C.F.3
-
26
-
-
85019702082
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
-
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 960-977
-
-
Smolen, J.S.1
Landewé, R.2
Bijlsma, J.3
-
27
-
-
79955156664
-
Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-The early RA network (ERAN)
-
Kiely P, Walsh D, Williams R, et al. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity-the early RA network (ERAN). Rheumatology 2011;50:926-31.
-
(2011)
Rheumatology
, vol.50
, pp. 926-931
-
-
Kiely, P.1
Walsh, D.2
Williams, R.3
-
28
-
-
84940744778
-
APLAR rheumatoid arthritis treatment recommendations
-
Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 2015;18:685-713.
-
(2015)
Int J Rheum Dis
, vol.18
, pp. 685-713
-
-
Lau, C.S.1
Chia, F.2
Harrison, A.3
-
29
-
-
85003681006
-
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
-
Smolen JS, Burmester G-R, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74.
-
(2016)
Lancet
, vol.388
, pp. 2763-2774
-
-
Smolen, J.S.1
Burmester, G.-R.2
Combe, B.3
|